pharmaphorum

AstraZeneca scores phase 3 win with novel complement drug danicopan

Prospects for AstraZeneca's oral Factor D inhibitor danicopan were looking poor after it failed a phase 2 trial in a rare kidney disease in 2020, but a new readout could reinvigorate the drug.
Mena FN

ALXN2040 (Danicopan) Emerging Drug Insights And Market Forecasts, 2032 - An Investigational, First-In-Class, Oral Proximal Factor D Inhibitor Developed By Achillion

This "Danicopan Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about danicopan for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A ...
Yahoo Finance

Paroxysmal Nocturnal Hemoglobinuria Treatment Advances with Comprehensive Danicopan Market Forecast to 2032

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global healthcare industry ...
PharmiWeb

NICE recommends Voydeya® (danicopan) with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with residual haemolytic anaemia

London, 22 October, 2024 – Alexion, AstraZeneca Rare Disease, has received a positive recommendation for Voydeya® (danicopan), from the National Institute for Health and Care Excellence (NICE), as an ...
Yahoo Finance

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing ...

WILMINGTON, Del., December 11, 2023--(BUSINESS WIRE)--Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard ...
Nasdaq

AstraZeneca : Phase III Trial Data Show Danicopan Sustained Clinical Improvements In PNH

(RTTNews) - AstraZeneca (AZN, AZN.L) said that positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 ...
Yahoo Finance

Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

Achillion Pharmaceuticals, Inc. ACHN announced that the European Medicines Agency (EMA) has granted PRIority Medicines (PRIME) designation to its oral factor D inhibitor danicopan (previously ACH-4471 ...
Pharmabiz

ALPHA phase III trial of danicopan add-on to Ultomiris or Soliris in patients with PNH who experience clinically significant EVH meets primary endpoint

A prespecified interim analysis of the ALPHA phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy Ultomiris (ravulizumab) ...
The Globe and Mail

Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal ...

A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS ® (ravulizumab ...
The American Journal of Managed Care

Factor D Inhibitor Danicopan Approved as Add-On Therapy for PNH

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
Pharmabiz

Long-term ALPHA phase III trial data shows danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients with PNH experiencing clinically ...

Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris (ravulizumab) ...